

TRICALS Trial Masterclass

FINAL PROGRAMME

Wednesday 6 November 2019

Hotel Karel V, Utrecht

17:00 Registration

18:00 Optimizing your trial design with TRICALS



Leonard van den Berg
Professor of Neurology, UMC Utrecht,
the Netherlands

19:00 Networking dinner

Meet leading experts in ALS drug research

21:00 End of day 1

Thursday 7 November 2019

Railway museum, Utrecht

08:45 Welcome

Session 1

Chair: Leonard van den Berg

09:00 Why were clinical trials in ALS negative?



Christopher McDermott
Professor of Translational Neurology,
University of Sheffield, UK

9:40 Choosing the best outcome measures for ALS trials



Markus Weber
Professor of Neurology, Kantonsspital
St. Gallen, Switzerland

10:20 Coffee Break

Session 2

Chair: Angela Genge

10:50 Redefining trial duration: Long or short clinical trials?



Adriano Chiò
Professor of Neurology, University of
Torino, Italy

11:30 Risk-based eligibility: Predicting fast progressors



Ruben van Eijk
Clinical Epidemiologist, UMC Utrecht,
the Netherlands

12:10 Networking lunch

Session 3

Chair: Orla Hardiman

13:30 Biomarker-guided trials: Pros and cons



Philip van Damme
Professor of Neurology, UZ Leuven,
Belgium

14:10 Comparison of the EU and US regulatory landscape



Marie Trad
VP Therapeutic Area Head/CNS,
IQVIA Biotech

14:25 The key to building an effective network



Leyla Kragten
Director Scientific Networks, Julius
Clinical, the Netherlands

14:40 Getting your trial successfully funded



Melanie Leitner
ALS Investment Fund

14:55 Discussion

15:30 Coffee Break

Session 4

Chair: Caroline Ingre

15:50 Is there a future for platform trials, master protocols & innovative trial design



Kit Roes
Professor of Clinical Trial Methodology,
UMC Utrecht, the Netherlands

16:30 TRICALS: creating a highway to therapy



Ammar Al-Chalabi
Prof. of Neurology & Complex Disease
Genetics, King's College London, UK

17:00 End of masterclass

TRICALS